JMJD6 and breast carcinoma: Interestingly, Kaplan-Meier analysis using expression and survival data of breast cancer patients from TCGA (https://xena.ucsc.edu) showed that there was a trend towards a considerable shorter survival in patients with simultaneous upregulation of JMJD6 and EZH2 expression (Additional file 7).